Vytorin:  Wave Two - Impact of ENHANCE Trial

Specialties:

Vytorin: Wave Two -- Impact of ENHANCE Trial

A Survey of One-Hundred Three US-based PCP’s and Cardiologists

Price $2500

Deliverable: Survey with key findings.

Study Description:

Topic	Vytorin: Wave Two -- Impact of ENHANCE Trial
Respondent Type	Physicians
Specialties Covered	Primary Care and Cardiology
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website Duration: 10 minutes Size: 72 PCP’s and 31 Cardiologists for 103 respondents Fielding Dates: April 1^st to April 4^th, 2008

Objectives:

To determine the impact of the ENHANCE study on Vytorin and Zetia use.

Companies and Products Mentioned in This Report:

Company	Ticker Symbol	Product(s)
AstraZeneca	AZN	Crestor
Pfizer	PFE	Lipitor
Merck/Schering-Plough Pharmaceuticals	MRK/SGP	Vytorin
Merck/Schering-Plough Pharmaceuticals	MRK/SGP	Zetia
Merck & Co	MRK	Zocor

Inclusion Criteria and Respondent Demographics:

Inclusion Criteria

§ US-based

§ 2 to 30 years of experience post-training

§ Minimum of 75% professional time spent in clinical practice

§ Writes at least 20 prescriptions for Zetia and Vytorin (combined) in an average month

To purchase this report or request additional information, contact:

Reports become free one year after the publication date.

about us